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The aim of this work was to develop a new in vitro lipolysis-permeation model to predict the 16 
in vivo absorption of fenofibrate in self-nanoemulsifying drug delivery systems (SNEDDSs). 17 
More specifically, the in vitro intestinal lipolysis model was combined with the mucus-PVPA 18 
(Phospholipid Vesicle-based Permeation Assay) in vitro permeability model. Biosimilar mucus 19 
(BM) was added to the surface of the PVPA barriers to closer simulate the intestinal mucosa. 20 
SNEDDSs for which pharmacokinetic data after oral dosing to rats was available in the 21 
literature were prepared, and the ability of the SNEDDSs to maintain fenofibrate solubilized 22 
during in vitro lipolysis was determined, followed by the assessment of drug permeation across 23 
the mucus-PVPA barriers. The amount of drug solubilized over time during in vitro lipolysis 24 
did not correlate with the AUC (area under the curve) of the plasma drug concentration curve. 25 
However, the AUC of the drug permeated after in vitro lipolysis displayed a good correlation 26 
with the in vivo AUC (R2 > 0.9). Thus, it was concluded that the in vitro lipolysis–mucus-PVPA 27 
permeation model, simulating the physiological digestion and absorption processes, was able 28 
to predict in vivo absorption data, exhibiting great potential for further prediction of in vivo 29 
performance of SNEDDSs. 30 
 31 
Keywords: Gastrointestinal tract; In Vitro/In Vivo (IVIVC) Correlation; In vitro model; 32 
Lipid-based formulation; Oral drug delivery; Permeability; Poorly water-soluble drug; 33 
Precipitation; Self-emulsifying.  34 
3 
 
1. Introduction 35 
In the past decades, lipid-based drug delivery systems (LbDDSs) have attracted increasing 36 
attention due to their ability to improve the bioavailability of poorly water-soluble drugs1 via 37 
solubilization enhancement, supersaturation2, 3, permeation enhancement and lymphatic transport4.  38 
Among LbDDSs, self-nanoemulsifying drug delivery systems (SNEDDSs; mixture of oil, 39 
surfactant, co-surfactant and co-solvent) have especially been studied because of their ability to 40 
spontaneously form nanoemulsions after dispersion in an aqueous environment. Once entered into 41 
the gastrointestinal (GI) tract, these formulations are dispersed in the gastric and intestinal fluids 42 
and are concomitantly affected by digestive enzymes. These physiological processes result in the 43 
formation of a wide range of colloidal structures able to affect the solubilization of the 44 
administered drug, and thus impacting its absorption5. Although several studies have been carried 45 
out regarding the potential of LbDDSs as oral drug delivery systems3, 6-8 and several LbDDSs have 46 
reached the market9, the development of an optimal LbDDS is still regarded as a challenging 47 
process1. The main reason for this is that numerous excipients can be used for LbDDSs, and the 48 
selection of the appropriate excipients is a demanding procedure due to e.g. insufficient methods 49 
currently able to estimate the in vivo absorption profile5, 8. In this regard, the UNGAP 50 
(Understanding Gastrointestinal Absorption-related Processes) European COST Action Network 51 
has recently stressed the problems related to a poor comprehension of GI drug absorption, and has 52 
highlighted the current approaches and further developments needed in this field10. For instance, 53 
the in vitro intestinal lipolysis model has been developed to investigate the performance of 54 
LbDDSs prior to in vivo testing11. Even though the model provides valuable information on the 55 
lipolysis rate of a LbDDS, as well as drug solubilization during lipolysis of a LbDDS, recent 56 
studies have shown that the in vitro model does to not always predict the in vivo performance of 57 
LbDDSs in terms of drug absorption3, 8, 12. For instance, in the study by Michaelsen et al.12 the 58 
amount of fenofibrate found in the aqueous phase after in vitro lipolysis of three different 59 
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SNEDDSs (i.e. SNEDDS75, super-SNEDDS solution150 and super-SNEDDS suspension150) failed 60 
to correlate with in vivo drug absorption in rats, and it has been proposed that the lack of an 61 
absorption step in the in vitro lipolysis model could be the reason for the low correlation with in 62 
vivo data13. In parallel, numerous in vitro permeability models have been validated to mimic the 63 
intestinal mucosa and to assess drug absorption from different drug delivery systems (e.g. the 64 
Caco-2 model14; the PAMPA model15; the PVPA model16; the Permeapad™17; and the AMI 65 
system18). The PVPA (Phospholipid Vesicle-based Permeation Assay) in vitro barriers, composed 66 
of liposomes immobilized in and on top of nitrocellulose filters, have been established in the past 67 
decade and have proved to simulate the intestinal mucosa16. However, all the above-mentioned 68 
permeation models were developed without considering the GI digestion affecting LbDDSs. Since 69 
neither the in vitro lipolysis models nor the in vitro permeation models alone are able to provide a 70 
full picture of the physiological processes driving GI drug absorption from LbDDSs, they have 71 
recently been combined to allow the concomitant study of lipolysis and permeation. For instance, 72 
a cell-free artificial membrane, the Permeapad™, has been combined with the in vitro intestinal 73 
lipolysis model using porcine pancreatin as source of digestive enzymes6, 13. Moreover, a cell-74 
based system, the Caco-2 cell model, has been combined with the in vitro intestinal lipolysis 75 
utilizing immobilized microbial lipase as the digestive enzyme7, 19, 20. Several of these combined 76 
studies led to improved prediction of in vivo absorption data compared to the in vitro lipolysis 77 
models or in vitro permeation models alone13. Besides Keemink and Bergstrom19, where mucin 78 
from porcine stomach type III was used as a mean to protect the Caco-2 cell layer, all other models 79 
were designed without simulating the mucus layer covering the intestinal wall, thus not fully 80 
mimicking the physiological environment of the intestinal mucosa21. In fact, the mucus layer is the 81 
first barrier that a drug gets in contact with after entering the lumen, and the drug partition between 82 
the intestinal luminal fluids, the mucus layer and the intestinal epithelium can affect the extent of 83 
drug permeation21. Moreover, mucus has shown to affect the absorption of drugs, lipids and 84 
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nutrients, and lipid digestion products can conversely modulate the properties of this barrier22-24. 85 
Therefore, it is of key importance to include the mucus layer in such in vitro models, in order to 86 
be able to consider its impact on drug absorption. Thus, efforts have been made to simulate the 87 
mucus layer covering the GI tract and, as a result of this, an artificial biosimilar mucus (BM) has 88 
been developed25, and proved to resemble both the composition and the rheological properties of 89 
porcine intestinal mucus25, 26. 90 
In light of the importance of including mucus in combined in vitro lipolysis-permeation models, 91 
as described above, the present study aimed at evaluating if the PVPA in vitro permeability model 92 
covered with biosimilar mucus would be compatible with a digesting environment. Moreover, the 93 
model was tested in terms of its ability to predict the in vivo plasma exposure of fenofibrate (poorly 94 
water-soluble drug; LogP 5.827) from SNEDDS75, super-SNEDDS solution150 and super-SNEDDS 95 
suspension150 previously found by Michaelsen et al.
12, and thus lead to in vivo-in vitro correlation 96 
(IVIVC). 97 
 98 
2. Materials and methods 99 
2.1. Materials 100 
Bovine bile, bovine serum albumin (BSA), 4-bromophenyl-boronic acid (BBBA), calcein, 101 
cholesterol, fenofibrate, maleic acid, MES hydrate, magnesium sulphate, mucin from porcine 102 
stomach type II, pancreatin from porcine pancreas, soybean oil (long-chain (LC) glycerides), tris-103 
(hydroxymethyl)aminomethane (Tris) were products of Sigma Aldrich (St. Luis, MO, USA). 104 
Acetonitrile (High-Performance Liquid Chromatography, HPLC, grade), dimethyl sulfoxide 105 
(DMSO), ethanol (EtOH; Ph. Eur. Grade), methanol (MeOH; HPLC grade) sodium chloride 106 
(NaCl) were purchased from VWR (Herlev, Denmark). Calcium chloride dihydrate, sodium 107 
hydroxide were obtained from Merck (Darmstadt, Germany), whereas polysorbate 80 (Tween 80) 108 
and polysorbate 20 (Tween 20) were obtained from Fluka Chemie AG (Buchs, Switzerland). 109 
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Maisine 35-1 was kindly donated by Gattefossé (St. Priest, France) and Kolliphor RH-40 was 110 
kindly received from BASF (Ludwigshafen, Germany). Polyacrylic acid (Carbopol® 974P NF) 111 
was purchased from Lubrizol (Brussels, Belgium). E80 lipoid egg-phospholipids (80% 112 
phosphatidylcholine) and soy phospholipids (S-PC) were obtained from Lipoid (Ludwigshafen, 113 
Germany). All chemicals employed were of analytical grade. 114 
 115 
2.2. Methods 116 
 117 
2.2.1. Biosimilar mucus preparation 118 
Biosimilar mucus (BM) was prepared following the method described by Boegh et al.25. Briefly, 119 
Carbopol® was dissolved in a hypo-tonic buffer (10 mM MES buffer with 1.0 mM MgSO4 and 120 
1.3 mM CaCl2; pH 6.5) and mucin type II from porcine stomach was added. A lipid mixture was 121 
separately prepared in an isotonic buffer (10 mM MES buffer with 1.0 mM MgSO4, 1.3 mM CaCl2 122 
and 137 mM NaCl; pH 6.5) by mixing SPC, cholesterol and polysorbate 80. Finally, BSA and the 123 
lipid mixture were added to the Carbopol®-mucin mixture, in order to obtain the final 124 
concentrations: Carbopol® (0.9 % w/v), mucin type II from porcine stomach (5 % w/v), S-PC 125 
(0.18 % w/v), cholesterol (0.36 % w/v), polysorbate 80 (0.16 % w/v) and BSA (3.1 % w/v). The 126 
pH was carefully adjusted to 6.5 and the BM was stored at 4 °C overnight before its use. 127 
  128 
2.2.2. PVPA barrier preparation 129 
The PVPA barriers were prepared as previously described by Falavigna et al.28-29. Briefly, 130 
liposomes with two different size distributions (0.4 and 0.8 µm) were obtained using the thin-film 131 
hydration technique followed by extrusion. In order to provide immobilization and fusion of the 132 
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liposomes, they were centrifuged and freeze-thawed on top of nitrocellulose membrane filters 133 
fused to Transwell inserts (surface area 0.33 cm2) (Corning Inc., New York, USA). 134 
 135 
2.2.3. Preparation of SNEDDSs 136 
SNEDDS composed of soybean oil (27.5 % w/w), Maisine 35-1 (27.5 % w/w), Kolliphor RH-40 137 
(35 % w/w) and absolute ethanol (10 % w/w) were prepared following the method previously 138 
described by Michaelsen et al.12. Firstly, soybean oil, Maisine 35-1 and Kolliphor RH-40 were 139 
heated at 50 °C, and subsequently Maisine 35-1 and soybean oil were mixed in a 1:1 (w/w) ratio; 140 
Kolliphor RH-40 was then added to the mixture, which was left to stir until cooled down to room 141 
temperature. Lastly, absolute ethanol was added, and the SNEDDS pre-concentrate was stirred 142 
until homogeneity was reached.  143 
Three fenofibrate-loaded SNEDDSs were prepared by adding different amounts of the drug to the 144 
pre-concentrate. The equilibrium solubility (Seq) of fenofibrate in the pre-concentrate was 145 
previously reported to be 88.5 mg/g8. SNEDDS75 was prepared by adding drug corresponding to 146 
75 % of the fenofibrate Seq to the pre-concentrate (Table 1) and leaving it to stir at room 147 
temperature (23-25 °C) to aid the dissolution process until use. The super-SNEDDS suspension150 148 
was prepared in the same way as the SNEDDS75, but 150% of the Seq was added to the pre-149 
concentrate. The super-SNEDDS solution150 was prepared by adding drug corresponding to 150 150 
% of the fenofibrate Seq to the pre-concentrate (Table 1), which was then bath-sonicated for 30 151 






Table 1: Fenofibrate loading and form in the prepared SNEDDSs. 156 
Name Drug concentration  
(% of drug Seq in the pre-concentrate) 
Drug state 
SNEDDS75 75 In solution 
Super-SNEDDS solution150 150 In solution 
Super-SNEDDS suspension150 150 In suspension 
 157 
 158 
2.2.4. Solubility studies to select acceptor medium for permeation experiment 159 
The solubility of fenofibrate in different aqueous media was tested in order to select a good 160 
acceptor medium for the permeation experiments. The method employed followed the procedure 161 
described by Berthelsen et al.30. Briefly, 10 mg of fenofibrate were suspended in 15 mL of either 162 
PBS pH 7.4; Tween 20 5 mg/mL; DMSO 10 mg/mL; DMSO 40 mg/mL; BSA 4% (w/v) or BSA 163 
1% (w/v) (all media were prepared in PBS pH 7.4) and the suspensions were left to rotate at 37 °C 164 
for a total of 48 hours. The tubes containing the suspensions were centrifuged after 1, 4, 24 and 48 165 
hours of incubation for 10 minutes at 6500×g, and samples (1 mL) from the supernatant were 166 
withdrawn and centrifuged for 10 minutes at 19,000×g. The supernatant was finally diluted with 167 
MeOH prior to the quantification of fenofibrate solubilized in the chosen medium. Difference in 168 
fenofibrate solubility in one specific medium below 5% between two consequent time points was 169 
considered enough to state that the solubility was reached. The quantification of fenofibrate was 170 
carried out by HPLC (Dionex UltiMate 3000 pump, ASI 100 automated sample injector, Dionex 171 
Ultimate 3000 detector; all from Thermo Fischer, Waltham, MA, USA), using a Phenomenex 172 
Kinetix 5u XB-C18 100A column (100 x 4.6 mm; Phenomenex, Torrance, CA, USA). Fenofibrate 173 
was detected at a wavelength of 288 nm, with a retention time of approximately 2.5 minutes. The 174 
mobile phase was composed of 20% purified water and 80% of MeOH and the flow was set to 1 175 
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mL/min. In the case of BSA (1 and 4% w/v) as acceptor medium, acetonitrile was added to the 176 
samples in order to precipitate the BSA prior to the quantification via HPLC. The solubility in 177 
each medium was tested in triplicate (n = 3). 178 
 179 
2.2.5. Compatibility of the PVPA barriers with donor and acceptor media 180 
Before the assessment of fenofibrate permeation from SNEDDSs, the permeation of calcein (5.5 181 
mM) was tested to assess the compatibility of the PVPA barriers with the different donor media 182 
(Fig. 1B) using PBS pH 7.4 as the acceptor medium. Once the donor media had been evaluated, 183 
the compatibility of the PVPA barriers with different acceptor media (see Section 2.2.4) was 184 
studied. All experiments were performed at 37 °C. For the experiment being performed in the 185 
presence of BM, the mucus layer (50 µL) was carefully pipetted on top of the PVPA barriers and 186 
left to incubate for 10 minutes prior to the addition of the donor medium (Fig. 1B). The donor 187 
samples (100 µL; Fig. 1B) were directly pipetted on top of the barriers (with or without BM). The 188 
barriers were then placed into an acceptor Transwell well containing the acceptor medium (600 189 
µL) and were moved into new wells with the same medium after 2, 4, 5 and 6 hours to uphold sink 190 
conditions. At the end of the permeation experiment, calcein Papp was calculated and the electrical 191 
resistance across the PVPA barriers was measured using a Millicell-ERS volt-ohmmeter 192 
(Millicell-ERS, Millipore, USA). The measured electrical resistance was then subtracted with the 193 
electrical resistance of the nitrocellulose filter (119 Ohm), and the resulting value was normalized 194 
with the surface area of the PVPA barriers (0.33 cm2). The quantification of calcein was carried 195 
out using a Tecan Infinite M200 fluorimeter/spectrophotometer (Salzburg, Austria; Software: 196 
Magellan) at excitation wavelength of 485 nm and emission of 520 nm (gain: 70). For each 197 
condition tested, 12 PVPA barriers were used (n = 12). Values of calcein Papp below 0.06 · 10
-6 198 





2.2.6. In vitro lipolysis of fenofibrate-loaded SNEDDSs 202 
The lipolysis of the SNEDDSs under fasted state conditions using the in vitro intestinal lipolysis 203 
model was carried out following the method described by Michaelsen et al.12 with minor 204 
adjustments. In particular, the SNEDDSs were weighed into a thermostated vessel (37 °C), and 205 
subsequently 26 mL of fasted state intestinal medium was added (bile bovine 2.95 mM, calcium 206 
chloride 1.40 mM, calcein 5.50 mM, maleic acid 2.00 mM, sodium chloride 146.80 mM, S-PC 207 
0.26 mM, tris 2.00 mM; pH 6.50). 208 
The amount of SNEDDS added into the vessel was adjusted to obtain a final fenofibrate 209 
concentration of 480 µg/mL in all experiments, following the procedure described by Michaelsen 210 
et al.12. The pancreatic lipase solution was prepared by mixing the crude lipase extract with 5 mL 211 
of intestinal medium in the absence of calcein , centrifuging the mixture for 7 minutes at 6500×g, 212 
and collecting the supernatant. Lipolysis was initiated by adding 4 mL of pancreatic lipase solution 213 
to the thermostated reaction vessel (final activity of 550 USP/mL). The decrease in pH due to the 214 
release of free fatty acids from the digested SNEDDS was countered by the use of an automated 215 
pH-stat (Metrohm Titrino 744, Tiamo version 1.3, Herisau, Switzerland) with automated addition 216 
of NaOH (0.4 M) in order to keep the pH constant at 6.5. The calcium chloride present in the 217 
intestinal medium allowed for a continued lipolysis by removing the free fatty acids by 218 
precipitation, and thereby avoiding inhibition of the lipase activity.  219 
Samples (1 mL) were taken from the vessel after dispersion (i.e. before lipase addition; 0 minutes) 220 
and after 30 minutes of lipolysis, both to be used for the analysis of fenofibrate distribution 221 
between the aqueous and pellet phase, and for permeability experiments. Lipolysis in the samples 222 
used for the investigation of the fenofibrate distribution was inhibited by the addition of 5 µL 223 
BBBA (1 M in MeOH). The inhibited samples (time point 0 and 30 minutes) were centrifuged for 224 
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phase separation (19,000×g for 10 minutes), and the concentration of fenofibrate in the aqueous 225 
phase was quantified by HPLC after appropriate dilution in MeOH following the method described 226 
in Section 2.2.4. To quantify the total amount and determine the recovery of fenofibrate in the 227 
lipolysis vessel, samples were taken before centrifugation and analysed by HPLC. The lipolysis 228 
was carried out four times for each SNEDDS (n = 4). The permeability samples were directly 229 
pipetted (100 µL) on top of the mucus-PVPA barriers to study the permeation of fenofibrate (see 230 
Section 2.2.7). The lipolysis of the SNEDDSs was not inhibited for the permeation samples after 231 
30 minutes of lipolysis.  232 
 233 
2.2.7. Fenofibrate permeation using the mucus-PVPA model 234 
Once the preferred donor and acceptor media for the permeation experiment had been selected 235 
(Section 2.2.5), the permeation of fenofibrate from SNEDDS (i.e. SNEDDS75, super-SNEDDS 236 
solution150, super-SNEDDS suspension150) was tested using the mucus-PVPA barriers. Calcein 237 
was added to all donor media, in order to enable an in-line assessment of the mucus-PVPA barrier 238 
integrity (data not shown). As described above (Section 2.2.5), BM was pipetted (50 µL) on top 239 
of the PVPA barriers 10 minutes prior to the addition of the donor sample (100 µL). The donor 240 
sample was either obtained after dispersion of SNEDDSs in the intestinal medium (i.e. sample 241 
before lipolysis; time point 0 minutes), or after 30 minutes of lipolysis (i.e. digesting SNEDDSs 242 
in intestinal medium; no lipolysis inhibition). The barriers were then placed into an acceptor 243 
Transwell well  containing the acceptor medium (600 µL) and were moved into new wells with 244 
the same medium after 2, 4, 5 and 6 hours to uphold sink conditions. The electrical resistance 245 
across the PVPA barriers was measured after 6 hours to test if the integrity of the barriers was 246 
maintained, as discussed above (Section 2.2.5). The quantification of calcein and fenofibrate in 247 
the acceptor compartment was carried out using a Tecan Infinite M200 248 
fluorimeter/spectrophotometer (Salzburg, Austria; Software: Magellan) at excitation wavelength 249 
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of 485 nm and emission of 520 nm (gain: 70) for calcein and 288 nm for fenofibrate. For each 250 
condition tested, six PVPA barriers were used (n = 6). 251 
 252 
2.2.8. Calculations 253 











Where dQ/dt expresses the flux at the steady state (nmol/s), A is the surface area of the PVPA 256 
barriers (0.33 cm2) and Cd the initial fenofibrate/calcein concentration in the donor compartment 257 
(nmol/mL). 258 
The area under the curve (AUC) was calculated using GraphPad Prism 7.03 (GraphPad Software, 259 
San Diego, CA, USA), which employed a linear trapezoidal model from t = 0 to t = 6 h. 260 
 261 
2.2.9. Statistical analysis 262 
GraphPad Prism 7.03 was employed for the statistical analysis of the presented results (GraphPad 263 
Software, San Diego, CA, USA). The data was analysed using one-way ANOVA followed by 264 
Šidák post hoc test to detect significant differences (p < 0.05) when comparing three or more sets 265 
of data. If a comparison between two sets of data was made, student t-test was employed (p < 266 
0.05). 267 
 268 
3. Results and discussion 269 
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In this study, the development and validation of the in vitro lipolysis – mucus-PVPA permeation 270 
model was carried out. Biosimilar mucus (BM) was added on top of the PVPA barriers, leading to 271 
a better simulation of the intestinal mucosa, which also contains a mucus layer.  272 
The integrity of the PVPA barriers was evaluated in the presence of BM, simulated intestinal 273 
medium, undigested and digesting SNEDDSs. The lipolysis of fenofibrate-loaded SNEDDSs was 274 
studied using the in vitro intestinal lipolysis model, followed by the drug permeation assessment 275 
using the mucus-PVPA barriers. Finally, the correlation of in vitro lipolysis and lipolysis-276 
permeation data with in vivo plasma data of fenofibrate in rats was determined. The type of IVIVC 277 
assessed in this study can be referred to as a Level D correlation, and it is considered a qualitative 278 
correlation which can be used in the development of new formulations31. 279 
 280 
3.1. Lipolysis-permeation model setup  281 
3.1.1. Donor medium selection 282 
The compatibility of the PVPA barriers, with and without mucus, with the donor medium 283 
compositions in Fig. 1B, using PBS pH 7.4 as acceptor medium, was evaluated by assessing the 284 
permeation of the hydrophilic marker calcein, and the electrical resistance across the barriers at 285 
the end of the permeation assay (see Section 2.2.5). 286 
As it can be observed in Fig. 1, the PVPA barriers were able to maintain their functionality in all 287 
the tested donor media in the presence of BM. In the absence of BM, the medium with undigested 288 
SNEDDS75 (Fig. 1, Setup 5) led to barrier impairment; calcein Papp was 0.29 · 10
-6 cm/s and the 289 
electrical resistance was 208 Ohm · cm2, which were both values outside the limits set for intact 290 
barriers (i.e. calcein Papp above 0.06 · 10
-6 cm/s and electrical resistance below 290 Ohm · cm2 291 
indicate loss of barrier integrity28). However, the digested SNEDDS75 in the donor compartment 292 
showed to be compatible with the barrier also in the absence of mucus (Fig. 1, Setup 7). The 293 
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difference in barrier compatibility between the undigested and digested SNEDDS75 might be due 294 
to the colloidal structures that are generated during the lipolysis of SNEDDSs. SNEDDS75 before 295 
lipolysis display a very distinct structure characterized by nano-emulsion droplets, while during 296 
lipolysis their lipid fractions result in the formation of different colloidal structures, such as 297 
vesicles and micelles, composed of both lipolysis products and components present in the 298 
simulated intestinal medium12. 299 
BM, fasted state simulated intestinal medium, undigested SNEDDS75 (in the presence of BM) and 300 
digested SNEDDS75 (both with uninhibited and inhibited pancreatin) were compatible with the 301 
barriers (Fig. 1). As the presence of BM maintained barrier integrity with undigested SNEDDS75 302 
(Fig. 1, Setup 6), BM was applied on top of the barriers during the assessment of the permeation 303 
of fenofibrate from SNEDDSs before and after in vitro lipolysis. 304 
 305 
Fig. 1: A) PVPA barrier integrity expressed as apparent permeability (Papp) of calcein (5.5 mM) 306 
and electrical resistance across the PVPA barriers with different setups (Mean ± SD; n = 12). B) 307 
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Setups tested in terms of PVPA barrier compatibility with and without BM. PBS pH 7.4 was used 308 
as the acceptor medium. 309 
 310 
3.1.2. Acceptor medium selection 311 
The solubility of fenofibrate was determined in the acceptor medium for the permeation study 312 
described in Section 2.2.4. Higher solubility of the lipophilic drug in the acceptor compartment of 313 
the PVPA model would enable a larger amount of drug to permeate, thereby easing the 314 
quantification of the amount of permeated drug. As can be observed in Table 2, the highest 315 
solubility of fenofibrate was in Tween 20 5 mg/mL and BSA 4% w/v. Moreover, DMSO 316 
significantly increased the solubility of fenofibrate at a concentration of 40 mg/mL, but not at 10 317 
mg/mL, when compared to PBS pH 7.4 (Table 2).  318 
 319 
Table 2: Equilibrium solubility of fenofibrate in different aqueous media prepared in PBS pH 7.4 320 
(Mean ± SD; n = 3). *Statistically significant difference in fenofibrate equilibrium solubility 321 
compared to PBS pH 7.4 (p < 0.05). 322 
Acceptor medium Equilibrium solubility 
(nmol/mL) 
PBS pH 7.4 0.48 ± 0.03 
DMSO 10 mg/mL 0.59 ± 0.08 
DMSO 40 mg/mL 0.82 ± 0.01* 
BSA 1% w/v 14.19 ± 0.13* 
BSA 4% w/v 58.02 ± 0.49* 
Tween 20 5 mg/mL 116.71 ± 5.73* 
 323 
 324 
Only DMSO (1-40 mg/mL) has previously been investigated regarding its compatibility with the 325 
PVPA barriers32, and showed not to impair the integrity of the barriers up to a concentration of 40 326 
mg/mL. Thus, to select the best acceptor medium, the functionality of the barriers in the presence 327 
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of each acceptor medium was investigated before performing permeation experiments, while using 328 
calcein solution (in PBS pH 6.5; 5.5 mM) on the donor side. As can be seen in Fig. 2 the barriers 329 
maintained their integrity in the presence of PBS pH 7.4 and DMSO (10 and 40 mg/mL). In 330 
contrast, BSA (1 and 4% w/v) and Tween 20 5 mg/mL caused barrier impairment, as demonstrated 331 
by an increased calcein Papp and decreased electrical resistance. Based on the effect on PVPA 332 
barrier integrity and the solubility of fenofibrate, DMSO 40 mg/mL was chosen as the acceptor 333 
medium in the fenofibrate permeation studies. 334 
 335 
 336 
Fig. 2: PVPA barrier integrity expressed as apparent permeability (Papp) of calcein (5.5 mM) and 337 
electrical resistance across the barriers with different media in the acceptor compartment, and 338 
calcein 5.5 mM in the donor compartment (in PBS pH 6.5). (Mean ± SD; n = 12). 339 
 340 
3.2. In vitro lipolysis of fenofibrate-loaded SNEDDSs 341 
Three SNEDDSs (SNEDDS75, super-SNEDDS solution150 and super-SNEDDS suspension150) 342 
were analysed in terms of their capability of solubilizing fenofibrate after 30 minutes of in vitro 343 
lipolysis. Fig. 3 depicts the distribution of fenofibrate in the aqueous and the pellet phase before 344 
(0 min) and after (30 min) lipolysis. For SNEDDS75, little to no precipitation was observed both 345 
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before (0 min) and after (30 min) lipolysis, while for the super-SNEDDS solution150, precipitation 346 
of fenofibrate was observed at the start of lipolysis and after 30 minutes.  In the case of the super-347 
SNEDDS suspension150, the presence of drug precipite was pronounced both after dispersion (0 348 
min) and after lipolysis (30 min), and a significant increase over time (p < 0.05) was observed 349 
when comparing the amount of precipitate before and after lipolysis (Fig. 3). The differences 350 
between the SNEDDSs can be due to that twice as much SNEDDS75 was added, compared to the 351 
super-SNEDDS solution150 and the super-SNEDDS suspension150, in order to keep the fenofibrate 352 
concentration constant in the lipolysis vessel. This lower amount of lipid caused a decrease in drug 353 
solubilization and an increase in drug precipitation. 354 
 355 
 356 
Fig. 3: Relative amount of fenofibrate present in the aqueous phase (grey) and pellet phase (black) 357 
during in vitro intestinal lipolysis of SNEDDS75, super-SNEDDS solution150 and super-SNEDDS 358 
suspension150. (Mean ± SD; n = 4). * Statistical difference between the percentages of fenofibrate 359 
in solution after 0 minutes compared to 30 minutes of lipolysis. 360 
 361 
When comparing the two super-SNEDDSs, containing the same amount of lipid vehicle, the 362 
presence of precipitated fenofibrate was more pronounced for the super-SNEDDS suspension150 363 
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(Fig. 3). This is due to the nature of the super-SNEDDS suspension150 where the drug is only 364 
partially dissolved, whereas the drug is completely dissolved in the super-SNEDDS solution150. 365 
Michaelsen et al.12, studied the same fenofibrate-containing SNEDDSs, and the impact of 366 
fenofibrate load and SNEDDSs lipolysis on drug solubilization and absorption was evaluated via 367 
an in vivo pharmacokinetic study in rats and in vitro lipolysis. The results depicted in Fig. 3 are in 368 
accordance with the in vitro lipolysis data obtained by Michaelsen et al.12. Even though the ranking 369 
in terms of drug precipitation of the three SNEDDSs was the same as the findings in the present 370 
study, the percentage of drug precipitated during lipolysis was higher in the results presented by 371 
Michaelsen et al.12. The difference in drug precipitation between the two studies can be explained 372 
by the different experimental setups of the in vitro lipolysis applied in the two studies: in the 373 
present study, calcium was added to the simulated intestinal medium prior to lipolysis (initial/bolus 374 
addition of calcium) to simplify the experimental setup, whereas in the study by Michaelsen et 375 
al.12 calcium was continuously added during lipolysis to control the rate of lipolysis (dynamic 376 
addition of calcium). It has previously been demonstrated that initial and continuous addition of 377 
calcium can lead to differences in terms of drug precipitation during lipolysis of LbDDSs, and that 378 
the calcium concentration can also have an effect on the extent of lipolysis33. 379 
 380 
3.3. In vivo absorption-in vitro lipolysis correlation 381 
In the study by Michaelsen et al.12,  the super-SNEDDS solution150 had a superior in vivo 382 
performance after oral dosing to rats (i.e. higher AUC0-30h, in vivo and Cmax) compared to SNEDDS75 383 
and super-SNEDDS suspension150 (Table 3). This was not correlating with the observed drug 384 
solubilisation during in vitro lipolysis, where SNEDDS75 led to a higher drug solubilization. Thus, 385 
Michaelsen et al.12 were not able to find a correlation between the in vivo absorption and the drug 386 




Table 3: Area under the curve (AUC) resulting from fenofibrate absorption during in vivo studies 389 
in rats (*12, AUC0-30h, in vivo), % of fenofibrate found in the aqueous phase after 30 min of in vitro 390 
lipolysis,  and AUC resulting from the mass transfer of fenofibrate permeated across the mucus-391 
PVPA barriers (AUC0-6h, perm) before (0 min) and after (30 min) in vitro lipolysis from super-392 
SNEDDS solution150, SNEDDS75 and super-SNEDDS suspension150. Values labelled with the 393 






AUC0-30h, in vivo (µg·h/mL) in 
vivo rats* 
 
148.0 ± 47.5a, b 
 
88.3 ± 20.9a 
 
58.1 ± 16.9b 
 
Fenofibrate (%) in the aqueous 
phase after 30 min of in vitro 
lipolysis 
 
91.7 ± 1.11 
 
98.6 ± 2.1 
 
61.8 ± 11.9 
 
AUC0-6h, perm (nmol·h) in vitro 
mucus-PVPA: fenofibrate 
permeation before lipolysis 
 
17.0 ± 1.6c 
 
14.0 ± 1.2 
 
9.9 ± 2.2c 
 
 
AUC0-6h, perm (nmol·h) in vitro 
mucus-PVPA: fenofibrate 




17.0 ± 0.8d, e 
 
 
12.0 ± 1.0d 
 
 
8.7 ± 1.1e 
 395 
 396 
In accordance with the findings from Michaelsen et al.12, the present study did not find a 397 
correlation between the drug solubilized during in vitro lipolysis (Section 3.2) and the in vivo 398 
plasma data (R2 = 0.397; Fig. 4, Table 3), highlighting the fact that in vitro solubilization alone 399 
cannot predict the in vivo absorption of fenofibrate from the SNEDDS analyzed in this study. Even 400 
though it is generally assumed that the SNEDDS able to maintain the most drug in solution during 401 
lipolysis leads to the highest bioavailability34, it should be noted that the amount of fenofibrate in 402 
the aqueous phase during in vitro lipolysis is in a dynamic equilibrium between free drug and drug 403 
solubilized in vesicles and other colloidal structures resulting from the lipolysis products (e.g. free 404 
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fatty acids and monoglycerides) and their interaction with bile salts and phospholipid in the 405 
medium13. Only the free drug is available for absorption, and therefore it is of interest to quantify 406 
this, by adding a permeation step to the in vitro lipolysis. 407 
 408 
 409 
Fig. 4: Fenofibrate (%) found in the aqueous phase (AP) after 30 min of in vitro lipolysis as a 410 
function of the AUC 0-30h, in vivo from the plasma curve after oral dosing in rats (Michaelsen et al., 411 
201912) of super-SNEDDS solution150 (grey circle), SNEDDS75 (black square) and super-412 
SNEDDS suspension150 (white triangle). 413 
 414 
3.4. In vitro permeation 415 
The permeation of fenofibrate across the mucus-PVPA barriers following administration of three 416 
different SNEDDSs was evaluated before (0 min) and after (30 min) in vitro lipolysis. This allowed 417 
the investigation of whether fenofibrate permeation was influenced by i) SNEDDSs composition 418 
and ii) lipolysis of the SNEDDSs. The in-line assessment of the mucus-PVPA barrier integrity 419 
carried out by measuring the permeation of calcein confirmed the correct functionality of the 420 
mucus-PVPA barriers (data not shown), and confirmed that the componenets present in the donor 421 
compartment of the permeation barriers did not affect the mucus-PVPA barriers integrity.  422 
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As can be observed from Fig. 5, both before and after lipolysis, the super-SNEDDS solution150 423 
allowed the highest permeation of fenofibrate, followed by the SNEDDS75 and the super-SNEDDS 424 
suspension150. Even though the ranking of the three SNEDDSs was the same before (Fig. 5A) and 425 
after lipolysis (Fig. 5B), differences in the permeation profiles in the two conditions led to 426 
differences in AUC0-6h, perm (Table 3). The AUC0-6h, perm for the undigested super-SNEDDS 427 
solution150 was significantly higher than for the super-SNEDDS suspension150, but not the 428 
SNEDDS75. After 30 minutes of in vitro lipolysis, the AUC0-6h, perm for the super-SNEDDS 429 
solution150 was significantly higher than the AUC0-6h, perm for both the super-SNEDDS 430 
suspension150 and the SNEDDS75 (Table 3). This is in accordance with the in vivo data presented 431 
by Michaelsen et al.12 where the ranking of the in vivo AUC0-30h, in vivo was: super-SNEDDS 432 
solution150 > SNEDDS75 > super-SNEDDS suspension150 (Table 3). The difference between the 433 
AUC0-6h, perm before and after lipolysis can be explained by a change in drug concentration in the 434 
aqueous phase upon lipolysis. The nanoemulsion droplets of SNEDDS formed after dispersion in 435 
the intestinal medium (i.e. before in vitro lipolysis) can have a different impact on drug 436 
solubilization compared to the colloidal structures formed during lipolysis. This will especially 437 
impact the equilibrium between the amount of drug free in solution and the one associated with 438 






Fig. 5: Cumulative amount of fenofibrate permeated across the mucus-PVPA barriers from super-443 
SNEDDS solution150 (grey circle), SNEDDS75 (black square) and super-SNEDDS suspension150 444 
(white triangle) A) before (0 min) and B) after (30 min) lipolysis. (Mean ± SD; n = 6). 445 
 446 
The results discussed thus far demonstrate that, even though the total drug concentration in the 447 
donor compartment was the same (480 µg/mL) for all the analysed SNEDDSs, the amount of 448 
fenofibrate permeating through the barriers was affected by the SNEDDS in the donor 449 
compartment. Moreover, even though the in vitro lipolysis showed that the SNEDDS75 resulted in 450 
the highest amount of drug solubilized in the aqueous phase (Fig. 3), the super-SNEDDS 451 
solution150 exhibited the highest permeation (Fig. 5). Thomas et al.
35 have demonstrated that drug 452 
precipitation following lipolysis of super-SNEDDS solutions does not necessarily translate to 453 
lower in vivo drug absorption. The difference in drug permeation between the super-SNEDDS 454 
solution150 and SNEDDS75 can be due to the partitioning of the drug between being free in solution 455 
and in the colloidal structures, formed upon dispersion/lipolysis of the SNEDDS on top of the 456 
permeation barriers. For SNEDDS75, the lipid content is higher, and more drug can be associated 457 
to the colloidal structures, thus not being able to permeate. In contrast, for super-SNEDDS 458 
solution150,  the lower lipid content can lead to a higher amount of drug being free in solution, and 459 




3.5. In vivo absorption-in vitro permeation correlation 462 
To assess the correlation between in vitro and in vivo data, the in vitro AUC0-6h, perm from the 463 
fenofibrate permeation was depicted as a function of the in vivo AUC0-30h, in vivo  (Table 3
12) in Fig. 464 
6. The correlation of the permeation data after 30 minutes of in vitro lipolysis was better (Fig. 6B, 465 
R2 = 0.9952) compared to the permeation of fenofibrate from undigested SNEDDSs (Fig. 6A, R2 466 
= 0.9255), highlighting the positive impact of the presence of lipolysis on the IVIVC. Comparing 467 
these findings to Fig. 4, it is clear that for the investigated SNEDDSs, the amount of drug 468 
solubilised during in vitro lipolysis studies alone cannot predict the in vivo absorption of 469 
fenofibrate, while an additional permeation step can enable a prediction of the performance of 470 
SNEDDS in vivo. 471 
 472 
 473 
Fig. 6: In-vivo-in-vitro correlation (IVIVC) of in vivo plasma exposure (Michaelsen et al., 201912) 474 
and in vitro fenofibrate permeation across the mucus-PVPA barriers A) before (0 min) and B) after 475 
(30 min) lipolysis from super-SNEDDS solution150 (grey circle), SNEDDS75 (black square) and 476 
super-SNEDDS suspension150 (white triangle). 477 
 478 
In the present study, the presence of the BM layer on top of the absorptive PVPA barriers permitted 479 
the development of a permeation model able to withstand a digesting environment (Fig. 1). 480 
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Moreover, the addition of BM on top of the PVPA barriers allowed for a better simulation of the 481 
intestinal mucosa, and possibly contributed to the estimation of the in vivo performance of the 482 
SNEDDSs tested by Michaelsen et al.12. As all the in vitro fenofibrate permeation experiments 483 
were performed in the presence of mucus, the comparison in terms of drug permeation between 484 
the presence and absence of the mucus layer could not be assessed. The hydrophilic mucus barrier 485 
in the mucus-PVPA model has previously shown to affect drug permeation depending on the 486 
physicochemical properties of the investigated drug, drug formulation and the simulated 487 
physiological conditions28, 29, 36, and it is thus regarded as an essential part of the artificial 488 
absorption barrier. The presence of mucus is also important as it has been shown that SNEDDSs 489 
can rapidly permeate across this layer thanks to the low interaction of their hydrophobic surface 490 
with the hydrophilic regions of mucus and thanks to their low droplet size, consequently enabling 491 
higher drug absorption37-38. Thus, the inclusion of mucus on top of an in vitro permeation 492 
membrane is crucial to simulate the environment that SNEDDSs would be presented to in vivo, 493 
and allows these drug delivery systems to explicate the positive effect on drug absorption related 494 
to their high mucus permeation. 495 
 496 
4. Conclusion 497 
In the present study, the in vitro lipolysis – mucus-PVPA permeation model was developed. The 498 
model allowed the combination of the assessment of drug distribution during lipolysis for 499 
fenofibrate-loaded SNEDDSs typical of the in vitro intestinal lipolysis model with the 500 
quantification of the fenofibrate permeation through an artificial membrane mimicking the 501 
intestinal epithelium (i.e. mucus-PVPA barrier). The barriers used in this work were more stable 502 
when lined with a mucus layer, thus being able to closely mimic the physiology of the intestinal 503 
mucosa and to improve the relevance of the model for oral absorption studies. The investigated 504 
SNEDDSs had different abilities to keep fenofibrate solubilized in the aqueous phase during in 505 
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vitro lipolysis, and led to different drug permeation profiles. No correlation was found between 506 
already published in vivo absorption and drug solubilisation during in vitro lipolysis (R2 < 0.4), 507 
whereas a satisfactory correlation was found between the same in vivo data with in vitro 508 
permeation data both before and after in vitro lipolysis (R2 > 0.9), highlighting the importance of 509 
the permeation step following lipolysis in the prediction of in vivo drug absorption. The 510 
combination of in vitro lipolysis with in vitro permeation led to a better correlation (R2 = 0.9952) 511 
compared to absence of lipolysis (R2 = 0.9255). However, the satisfactory correlation in the 512 
absence of lipolysis suggests that this step might not be necessary. In order to validate this 513 
statement, further studies with other types of SNEDDSs need to be carried out.  514 
By applying the in vitro lipolysis – mucus-PVPA permeation model, it was possible to mimic 515 
physiological processes (i.e. lipolysis and permeation) and to correlate the amount of fenofibrate 516 
permeated in vitro with the AUC after oral dosing of the applied SNEDDSs in rats. 517 
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